PSEN2 and urinary bladder cancer: In a series of studies, it was shown that targeting CD46 chimeric Ad5/35 vectors could increase antitumor activity, decrease liver toxicity, and improve the safety profile of treatment for cervical (38), colorectal (39, 42) and bladder cancers (40), especially low-risk bladder cancer.